抗体

FGF23抗体

MBS854462

0.1毫克

215美元

多克隆

兔

未共轭

人类, 小鼠, 大鼠

免疫印迹, 酶联免疫吸附测定, 免疫细胞化学, 酶免疫法

抗体

FGF23抗体

FGF23

Fibroblast growth factor 23; FGF-23; Tumor-derived hypophosphatemia-inducing factor; HYPF;

fibroblast growth factor 23; Fibroblast growth factor 23; fibroblast growth factor 23; phosphatonin; tumor-derived hypophosphatemia inducing factor; fibroblast growth factor 23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factorCleaved into the following 2 chains:Fibroblast growth factor 23 N-terminal peptide; Fibroblast growth factor 23 C-terminal peptide

FGF23

FGF23;FGF23;ADHR;FGFN;HYPF;HPDR2;PHPTC;HYPF;FGF-23

FGF23_HUMAN

兔

人类, 小鼠, 大鼠

251

FGF23抗体检测内生水平总数FGF23蛋白

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1毫克/毫升

Store at -20 degree C for 1 year

免疫荧光(IF), 酶联免疫吸附测定(EIA)

IF: 1:100~1:500, ELISA: 1:20000

Reactivity Note: Human (Identities = 100%, Positives = 100%); Mouse (Identities = 85%, Positives = 85%); Rat (Identities = 85%, Positives = 85%)

Immunogen: The antiserum was produced against synthesized peptide derived from internal of human FGF23. Pathway: Growth Factors

Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells; Autophagy antibody

Yamashita T., Biochem. Biophys. Res. Commun. 277:494-498(2000). White K.E., Nat. Genet. 26:345-348(2000). Shimada T., Proc. Natl. Acad. Sci. U.S.A. 98:6500-6505(2001). ------------------------------------------------------------------------------------------------------------------------------------------

10190674

NP_065689.1

NM_020638.2

Q9GZV9

27,954 Da

Activated Point Mutants Of FGFR2 Pathway (645281); Adaptive Immune System Pathway (366160); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550); Disease Pathway (530764); Downstream Signal Transduction Pathway (106385); Downstream Signaling Events Of B Cell Receptor (BCR) Pathway (576250); Downstream Signaling Of Activated FGFR Pathway (160957); FGF Signaling Pathway (137989)

This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013]

FGF23: Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR). ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses. Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC). HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Belongs to the heparin-binding growth factors family. Protein type: Secreted, signal peptide; Cytokine; Secreted. Chromosomal Location of Human Ortholog: 12p13.3. Cellular Component: extracellular space; extracellular region. Molecular Function: growth factor activity; type 1 fibroblast growth factor receptor binding. Biological Process: epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; nerve growth factor receptor signaling pathway; negative regulation of hormone secretion; positive regulation of transcription, DNA-dependent; phosphate metabolic process; negative regulation of bone mineralization; cellular phosphate ion homeostasis; insulin receptor signaling pathway; innate immune response; negative regulation of osteoblast differentiation; phosphate ion homeostasis; cell differentiation; vitamin D catabolic process. Disease: Hypophosphatemic Rickets, Autosomal Dominant

0.1毫克

215美元